glp 1 pediatric obesity GLP-1 receptor agonists in and diabetes: a systematic review of efficacy, metabolic effects, and safety 🔬New review highlights GLP-1 receptor

Amgen is taking their own approach to weight loss with their investigational obesity drug #MariTide

Form / Delivery Method: Sublingual drops

Purpose of Review This review provides a comprehensive and scholarly examination of glucagon-like peptide-1 receptor (GLP-1R) agonists, tracing their evolution from glycemic control agents in diabetes mellitus (DM) to multifaceted therapeutics with expanding indications in cardiovascular, renal, and metabolic health

Furthermore, dual-action compounds engaging GLP-1 combined with glucose-dependent insulinotropic polypeptide (GIP) or glucagon pathways, alongside triple agonists incorporating all three receptors activation, have exhibited enhanced therapeutic potential

Victoza (liraglutide) is a once-daily injectable medication used to treat type 2 diabetes